Excess CCL3 in the setting of myelogenous leukemias and multiple myeloma has been shown to inhibit osteoblastic activity and activate osteoclastic bone resorption leading to overall loss of bone6,7,24. The gene discussed is CCL3; the disease is AL amyloidosis.